In December 2024, the Food and Drug Administration (FDA) approved the PD-1 inhibitor nivolumab (Opvido Qvantig) for use as a subcutaneous injection. Read on to learn more about this new approach ...

Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad ...

Argenx’s VYVGART Hytrulo prefilled syringe for self-injection has received FDA approval for the treatment of adult patients ...

The Vyvgart Hytrulo prefilled syringe is approved as a 20- to 30-second subcutaneous injection administered by a patient, ...

Safety profiles were comparable, with fewer treatment-related side effects in the subcutaneous group, though local injection site reactions were more common. The FDA approved subcutaneous Opdivo for ...

Vyvgart Hytrulo prefilled syringe for self-injection is approved as a 20-to-30-second subcutaneous injection administered by a patient, caregiver, or healthcare professional. The single-dose ...

The Vyvgart Hytrulo prefilled syringe is approved as a 20- to 30-second subcutaneous injection administered by a patient, caregiver, or health care professional.

Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the U.S. on October 1, and expects to hit peak adoption rates ...

will cancel out the injection’s convenience edge. Before Merck, Roche’s Tecentriq and Bristol Myers Squibb’s Opdivo both have subcutaneous formulations approved by the FDA.